“The first step is the hardest, and we now know exactly what we need to do to develop effective drugs. It’s exciting to think that future work will build on this, and we will soon have life-changing treatments to tackle this disease.”
However, experts warned that UK officials have much to do to prepare to deliver the drug, provided it gets regulatory approval.
“It’s safe to say that the NHS is not ready for a new era of dementia treatment,” Doctor Susan Kohlhaas, director of research at Alzheimer’s Research UK, said.
“We estimate that unless there are drastic changes in how people access specialist diagnostic tests for Alzheimer’s disease, only two percent of people eligible for drugs like lecanemab will be able to access them.”